With regards to TATs, the two investigational α-emitters PSMA-Thorium-227 and PSMA-Actinium-225 seem to be promising and could represent additional weapons to extend survival in the next future of prostate cancer patients. The gene discussed is FOLH1; the disease is Familial prostate cancer.